How We Prescribe and Monitor ADHD Medications

At Aspire ADHD, ADHD medication is prescribed only after a comprehensive clinical evaluation and when pharmacologic treatment is determined to be medically appropriate. Medication selection is individualized based on the patient’s age, ADHD symptoms, level of impairment, medical and psychiatric history, coexisting conditions, current medications, previous treatment response, potential side effects, and risk factors.

Stimulant medications are generally considered first-line pharmacologic treatments for ADHD and, on average, produce greater reductions in core ADHD symptoms than non-stimulant medications. However, stimulants are not appropriate for every patient. Certain cardiovascular conditions, active substance use disorders, a history of medication misuse or diversion, psychotic disorders, bipolar disorder, severe anxiety, tic disorders, and other medical or psychiatric conditions may require additional evaluation, stabilization, closer monitoring, or consideration of alternative treatments.

Non-stimulant medications may be considered when stimulants are ineffective, poorly tolerated, contraindicated, or when the potential risks of stimulant treatment outweigh the expected benefits. The decision to prescribe a stimulant or non-stimulant medication is made on an individual basis after careful consideration of the patient’s clinical history, treatment goals, and potential risks and benefits.

For preschool-aged children with ADHD, behavioral interventions and parent training are generally recommended as initial treatment approaches. Medication may be considered when symptoms remain moderate to severe, cause significant functional impairment, and do not adequately improve with appropriate behavioral interventions.

Because most stimulant medications are Schedule II controlled substances, patient safety and responsible prescribing are important parts of our treatment approach. Before initiating stimulant treatment, patients undergo a review of their medical and psychiatric history, current medications, cardiovascular risk factors, substance use history, and potential risk for medication misuse or diversion. The Prescription Drug Monitoring Program (PDMP) is reviewed as required and appropriate.

Additional evaluation or testing may be required based on the patient’s individual risk factors. This may include an electrocardiogram (ECG), laboratory testing, urine drug screening, review of previous medical records, consultation with another treating clinician, or medical or cardiac clearance before stimulant treatment is initiated or continued.

Patients prescribed stimulant medications are required to participate in regular follow-up appointments so that treatment effectiveness, medication adherence, and potential adverse effects can be monitored. Follow-up care may include monitoring of blood pressure, heart rate, weight, appetite, sleep, mood, psychiatric symptoms, and overall functioning.

Stimulant medications are generally initiated at an appropriate starting dose and adjusted gradually based on clinical response and tolerability. The goal of treatment is not simply to improve attention, but to achieve meaningful improvements in academic, occupational, social, and daily functioning while minimizing side effects and medication-related risks.

Aspire ADHD maintains controlled substance prescribing policies designed to promote patient safety, responsible medication use, and continuity of care. Patients receiving stimulant medications may be required to sign a controlled substance treatment agreement, complete urine drug screening or pill counts when clinically indicated, and obtain controlled substance prescriptions from one designated prescriber and pharmacy.

Early refills and replacement prescriptions for lost, stolen, damaged, or otherwise unavailable controlled medications are generally not provided. Medication changes and dose adjustments require appropriate clinical assessment and may require a scheduled appointment. Patients are responsible for maintaining required follow-up appointments and requesting routine refills within the timeframes established by Aspire ADHD.

Treatment plans are reviewed regularly and may be modified when a medication is ineffective, causes significant side effects, is not taken as prescribed, or when medical, psychiatric, or safety concerns arise. Stimulant treatment may be reduced, changed, temporarily held, or discontinued when continued prescribing is no longer considered medically appropriate.

Our goal is to provide individualized, evidence-based ADHD treatment that balances effective symptom management with careful monitoring, responsible prescribing, and long-term patient safety.